New combo therapy for lung cancer shows promise in early trial
NCT ID NCT03916419
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a new treatment approach for people with inoperable non-small cell lung cancer. It combined MRI-guided radiation therapy with chemotherapy and an immunotherapy drug called durvalumab. The goal was to see if this combination is safe and effective at controlling the cancer. The trial enrolled 26 participants and focused on reducing side effects and improving local tumor control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Durvalumab (Imfinzi) plus chemotherapy (paclitaxel and carboplatin) and radiation therapy
- What this could lead to
- If successful, this approach could offer a more precise and effective treatment for inoperable lung cancer, potentially improving local tumor control and survival.
- What could go wrong
- This is a small, single-arm phase 2 trial, so results may not apply to all patients. There are risks of side effects from radiation, chemotherapy, and immunotherapy, including lung inflammation and other toxicities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IIB NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- New hope: targeted pill before surgery for lung cancer
- New combo therapy shows promise for Hard-to-Treat lung cancer
- New combo therapy aims to boost lung cancer fight
- Lung cancer combo therapy trial stopped early
- Blood test may predict who benefits from lung cancer combo therapy